PFE - The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid
Summary
- April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection.
- Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff.
- FNCH is a casualty of setbacks at the beginning of the new medical field of Microbiomics.
- Seres share price has fallen from $9 in November, when the FDA announced the upcoming SER-109 decision date, to $5.50 for no good reason.
- Investors interested in the Microbiome might pay attention to Seres now.
For further details see:
The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid